

BIMECTIN ORAL PASTE

Ivermectin 18.7mg/g

INDICATIONS

Bimectin is indicated for the treatment of nematode or arthropod infestations in horses due to:

- Large strongyles
- Small Strongyles
- Lungworms (adult and immatures)
- Pinworms (adult and immatures)
- Ascarids (adults and third & fourth stage larvae)
- Hairworms (adults)
- Large-mouth stomach worms (adults)
- Neck threadworms (microfilariae)
- Intestinal threadworms (adults)
- Stomach bots (oral and gastric stages)
- Ivermectin is not effective against the encysted larval stages of the small strongyles



BENEFITS

- Gel formulation for ease of dose and absorption
- Apple flavoured for exceptional palatability
- Calibrated syringe for accurate dosage
- Broad spectrum ivermectin anthelmintic and boticide
- Proven safe in horses of all ages
- Broad spectrum activity against a wide range of debilitating and performance robbing parasites

PACKAGING

LIST NO.	UNIT PACKAGE	CASE SIZE
1BIM098	6.42g	24

Bimeda®
 Broomhill Road
 Tallaght
 Dublin 24, Ireland
 Tel: 1850-515253

See reverse side for full indications, administration and dosage.



www.bimeda.ie

BIMECTIN HORSE PASTE

PRESENTATION

A yellow gel-like, apple flavoured, paste of uniform consistency, containing 1.87% w/w Ivermectin.

USES

Bimectin Horse Paste is indicated for the treatment nematode or arthropod infestations in horses due to:

Large strongyles: *Strongylus vulgaris* (adults and 4th larval [arterial] stages),

S. edentatus (adults & 4th larval [tissue] stages), *S. equinus* (adults),

Triodontophorus spp. (adults),

Triodontophorus brevicauda,

Triodontophorus serratus. Small

Strongyles: Adult and immatures

(fourth stage larvae) small

strongyles or cyathostomes unless

otherwise stated. Ivermectin

is not effective against the

encysted larval stages of the

small strongyles.: *Coronocyclus*

spp., *Cyathostomum* spp.,

Cylicocyclus spp., *Cylicostephanus*

spp., *Cylicodontophorus* spp., ,

Parapoterostomum spp.,

Petrovinaema spp., *Poterostomum*

spp. Lungworms (adult and inhibited

fourth stage larvae): *Dictyocaulus*

arnfieldi Pinworms (adult and

inhibited fourth stage larvae):

Oxyuris equi Ascarids (adults

and third & fourth stage larvae):

Parascaris equorum Hairworms

(adults): *Trichostrongylus axei*

Large-mouth stomach worms

(adults): *Habronema muscae* Neck

threadworms (microfilariae):

Onchocerca spp. Intestinal

threadworms (adults): *Strongyloides*

westeri

Stomach bots: Oral and gastric

stages of *Gasterophilus* spp.

DOSAGE AND ADMINISTRATION

Administer orally as a single dose rate to horses at the recommended dose level of 0.2mg ivermectin per kilogram of bodyweight. Each syringe delivers 120mg ivermectin, sufficient to treat 600kg of bodyweight. Single administration. Bodyweight and dosage should be accurately determined prior to treatment.

DOSING INSTRUCTIONS

Each weight marking on the syringe plunger will deliver sufficient

paste to treat 100kg bodyweight. Unlock the knurled ring by making ¼ turn and slide the knurled ring up the plunger shaft so that the side nearest the barrel is at the prescribed weight marking. Turn the knurled ring ¼ turn to lock in place. Make sure the horse's mouth contains no feed. Remove the plastic cap from the tip of the nozzle. Insert the syringe into the horse's mouth at the inter-dental space. Advance the plunger as far as it will go, depositing the medication on the base of the tongue. Immediately raise the horse's head for a few seconds after dosing. The treatment schedule should be based on the local epidemiological situation.

CONTRA-INDICATIONS,

WARNINGS, ETC

Special warning for non-target species: The product has been formulated for use in horses only. Cats, Dogs, especially Collies, Old English Sheepdogs and related breeds or crosses, and also turtles and tortoises may be adversely affected by the concentration of ivermectin in this product if they are allowed to ingest spilled paste or have access to used syringes. Do not use in mares producing milk for human consumption. Studies performed in laboratory animals showed no teratogenic or embryotoxic affect of ivermectin at the recommended doses during therapy. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to risk/benefit analysis by the responsible veterinary surgeon. Some horses carrying heavy infection of *Onchocerca* microfilariae have experienced oedema and pruritus following dosing, assumed to be the result of death of large numbers of microfilariae. These signs resolve within a few days but symptomatic treatment may be advisable. Ivermectin is extremely dangerous to fish and aquatic life. Treated animals should not have direct access to surface waters and ditches during treatment. Parasite resistance to any particular class of anthelmintic may develop following frequent, repeated use of an anthelmintic of that class.

OVERDOSE

Mild transitory signs (slowed pupillary light response and depression) have been seen at a dose of 1.8mg/kg (9 times the recommended dose level). Other signs seen at higher doses includes mydriasis, ataxia, tremors, stupor, coma and death. The less severe signs have been transitory. No antidote has been identified; however, symptomatic therapy may be beneficial.

WITHDRAWAL PERIODS

Meat and offal 34 days. Not permitted for use in mares producing milk for human consumption.

OPERATOR WARNINGS

Do not eat, drink or smoke while handling the product. Avoid contact with skin and eyes. If accidental skin contact occurs, wash the affected area immediately with soap and water. If accidental eye exposure occurs, flush the eyes immediately with water and, if necessary, get medical attention. Wash hands after use. Extremely dangerous to fish and aquatic life. Do not contaminate surface waters or ditches with product or used containers. Any unused product or waste material should be disposed of in accordance with national requirements.

PHARMACEUTICAL PRECAUTIONS

Following intensive exposure to sunlight photolytic degradation of ivermectin may occur. This is a single dose product. Discard after use. Keep out of reach and sight of children.

LEGAL CATEGORY LM

PACKAGE QUANTITIES

High density polyethylene pre-filled dose-graduated disposable syringe containing 6.42 g of product.

VPA 10960/48/1

TAKE TIME



OBSERVE LABEL DIRECTIONS

www.bimeda.ie